Brokerage firm Jefferies Maintains its rating on Bellicum Pharmaceuticals Inc(NASDAQ:BLCM). In a research note issued to the investors, the brokerage major Raises the price-target to $22.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 9, 2016.
In a different note, On Aug 9, 2016, Citigroup said it Maintains its rating on Bellicum Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $11.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 8, 2016, Citigroup said it Upgrades its rating on Bellicum Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $11.00 per share. The shares have been rated ‘Buy’ by the firm. SunTrust Robinson Humphrey said it Initiates Coverage on Bellicum Pharmaceuticals Inc, according to a research note issued on Jun 3, 2016. The shares have been rated ‘Buy’ by the firm.
Bellicum Pharmaceuticals Inc (BLCM) shares turned negative on Wednesdays trading session with the shares closing down -0.88 points or -4.46% at a volume of 3,97,610. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $19.94. The peak price level was also seen at $19.94 while the days lowest was $18.7601. Finally the shares closed at $18.84. The 52-week high of the shares is $23.84 while the 52-week low is $7.24. According to the latest information available, the market cap of the company is $510 M.
Bellicum Pharmaceuticals Inc(BLCM) last announced its earnings results on Aug 8, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $101.00K. Analysts had an estimated revenue of $90.00K. Earnings per share were $-0.61. Analysts had estimated an EPS of $-0.57.
Several Insider Transactions has been reported to the SEC. On Jul 29, 2016, Kevin M. Slawin (Chief Technology Officer) sold 15,000 shares at $15.00 per share price.Also, On Jul 29, 2016, David M. Spencer (Chief Scientific Officer) sold 10,000 shares at $15.00 per share price.On Jun 6, 2016, Annemarie Moseley (COO/EVP Clinical Development) sold 25,000 shares at $13.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.